These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 624031)

  • 1. Toxicity of oral adjuvant chemotherapy in breast cancer.
    Murray JG; MacIntyre J; Leiberman DP; Leaper DJ
    Br Med J; 1978 Feb; 1(6110):408-9. PubMed ID: 624031
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral adjuvant therapy in breast carcinoma--a multicentre trial.
    Leiberman DP; Berstock DA; Houghton J; Kearney G
    Cancer Treat Rev; 1979 Jun; 6 Suppl():91-6. PubMed ID: 387233
    [No Abstract]   [Full Text] [Related]  

  • 3. Psychiatric morbidity and physical toxicity associated with adjuvant chemotherapy after mastectomy.
    Maguire GP; Tait A; Brooke M; Thomas C; Howat JM; Sellwood RA; Bush H
    Br Med J; 1980 Nov; 281(6249):1179-80. PubMed ID: 7427625
    [No Abstract]   [Full Text] [Related]  

  • 4. Adjuvant chemotherapy for early breast cancer.
    Smith IE
    Br Med J (Clin Res Ed); 1983 Aug; 287(6389):379-80. PubMed ID: 6409315
    [No Abstract]   [Full Text] [Related]  

  • 5. Melphalan and methotrexate in advanced breast cancer.
    Priestman TJ; Salaman PF
    Cancer Treat Rep; 1978 Dec; 62(12):2111-2. PubMed ID: 751718
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute toxicity during adjuvant chemotherapy for breast cancer: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience from 1717 patients receiving single and multiple agents.
    Glass A; Wieand HS; Fisher B; Redmond C; Lerner H; Wolter J; Shibata H; Plotkin D; Foster R; Margolese R; Wolmark N
    Cancer Treat Rep; 1981; 65(5-6):363-76. PubMed ID: 7016322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results.
    Gianni AM; Siena S; Bregni M; Di Nicola M; Orefice S; Cusumano F; Salvadori B; Luini A; Greco M; Zucali R; Rilke F; Zambetti M; Valagussa P; Bonadonna G
    J Clin Oncol; 1997 Jun; 15(6):2312-21. PubMed ID: 9196145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy with CCNU, melphalan, methotrexate, and prednisone (CAMP) in 35 patients with advanced breast cancer.
    Hansen M; Palshof T; Osterlind K; Hansen HH; Mouridsen H
    Cancer Treat Rep; 1977 Nov; 61(8):1603-5. PubMed ID: 922762
    [No Abstract]   [Full Text] [Related]  

  • 9. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anaphylaxis due to oral melphalan.
    Lawrence BV
    Cancer Treat Rep; 1980; 64(4-5):731-2. PubMed ID: 7427957
    [No Abstract]   [Full Text] [Related]  

  • 11. [Adjuvant chemotherapy of primary breast cancer].
    Heuson JC; Mattheiem WH
    Acta Chir Belg; 1977; 76(4):437-43. PubMed ID: 919991
    [No Abstract]   [Full Text] [Related]  

  • 12. [Leukemia in patients with breast carcinoma after adjuvant chemotherapy and/or postoperative radiotherapy].
    Sack H
    Strahlenther Onkol; 1995 Jul; 171(7):420-1. PubMed ID: 7631268
    [No Abstract]   [Full Text] [Related]  

  • 13. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
    Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y
    J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate-associated liver toxicity in a patient with breast cancer: case report and literature review.
    van Outryve S; Schrijvers D; van den Brande J; Wilmes P; Bogers J; van Marck E; Vermorken JB
    Neth J Med; 2002 Jun; 60(5):216-22. PubMed ID: 12365478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Breast neoplasms. Progress by means of adjuvant chemotherapy?].
    Senn HJ
    MMW Munch Med Wochenschr; 1980 Jan; 122(1):10-5. PubMed ID: 6767909
    [No Abstract]   [Full Text] [Related]  

  • 16. The case for adjuvant CMF chemotherapy in breast cancer. Has it been made?
    Levitt SH; Potish RA
    Cancer Clin Trials; 1981; 4(4):363-9. PubMed ID: 7032731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer.
    Smith IE; Powles TJ
    Oncology; 1993 Apr; 50 Suppl 1():9-15. PubMed ID: 8483562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute leukemia after adjuvant chemotherapy for breast cancer.
    Gabrail NY
    Mo Med; 1989 Oct; 86(10):689-90. PubMed ID: 2552279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Results of, and indications for adjuvant chemotherapy in breast cancer].
    Brunner KW; Goldhirsch A; Joss R; Sonntag RW; Tschopp L
    Schweiz Med Wochenschr; 1981 Jun; 111(23):838-45. PubMed ID: 7268339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of the toxicity of precautional chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in carcinoma of the breast in the first 700 treatment cycles].
    Sismondi P; Zola P; Galletto L; De Giovanni D; Giardina G
    Minerva Ginecol; 1979; 31(7-8):563-8. PubMed ID: 481814
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.